Limits...
Burden of herpes zoster and post-herpetic neuralgia in Sweden.

Nilsson J, Cassel T, Lindquist L - BMC Infect. Dis. (2015)

Bottom Line: Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages.The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient.The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

View Article: PubMed Central - PubMed

Affiliation: Mapi Group, Stockholm, Klarabergsviadukten 90D, SE-111 64, Stockholm, Sweden. Jonas.nilsson@optum.com.

ABSTRACT

Background: The societal economic burden of herpes zoster in Sweden is not well described today. This study is a top-down analysis of Swedish registers with the objective to describe the burden of herpes zoster and post-herpetic neuralgia in Sweden during 2011.

Methods: Data for inpatient care; outpatient primary and specialized cares; the prescriptions of drugs, sick leave and the number or diagnostic tests were collected from Swedish national databases. The incidence of the disease was estimated based on the number of prescriptions of antiviral drugs.

Results: The incidence of herpes zoster was estimated to 315 and 577 cases per 100,000 people for patients at all ages and > = 50 years, respectively. Almost 30,000 patients at all ages were diagnosed with herpes zoster and the societal cost to treat these patients, including the cost to treat those patients who later developed post-herpetic neuralgia, added up to nearly 227 MSEK (31.6 M€) which corresponds to 7,600 SEK (€870) per patient. The main contributors to the total cost for the treatment of HZ patients were primary care (43 %); sick leave (28 %); hospitalization (10 %) and specialist care (7 %). Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages. The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient.

Conclusions: The current study demonstrates that the burden of herpes zoster is significant in Sweden. The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

Show MeSH

Related in: MedlinePlus

The incidence of herpes zoster (HZ) and post-herpetic neuralgia (PHN) during 2011 (incidence per 100,000 persons)
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4493830&req=5

Fig1: The incidence of herpes zoster (HZ) and post-herpetic neuralgia (PHN) during 2011 (incidence per 100,000 persons)

Mentions: The incidence of HZ during 2011 is presented per age group in Fig. 1. In total, 29,900 (all ages) and 2,860 patients (> = 50 years) were diagnosed with HZ and PHN in Sweden during 2011, respectively. The corresponding number for patients 50 years and older with a diagnosis of HZ was 20,446. The incidence of HZ is clearly higher for the group of patients older than 50 years compared to the whole population with 577 and 315 cases per 100,000 persons, respectively (Fig. 1). The incidence of PHN was only estimated for patients older than 50 years to 81 cases per 100,000 persons.Fig. 1


Burden of herpes zoster and post-herpetic neuralgia in Sweden.

Nilsson J, Cassel T, Lindquist L - BMC Infect. Dis. (2015)

The incidence of herpes zoster (HZ) and post-herpetic neuralgia (PHN) during 2011 (incidence per 100,000 persons)
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4493830&req=5

Fig1: The incidence of herpes zoster (HZ) and post-herpetic neuralgia (PHN) during 2011 (incidence per 100,000 persons)
Mentions: The incidence of HZ during 2011 is presented per age group in Fig. 1. In total, 29,900 (all ages) and 2,860 patients (> = 50 years) were diagnosed with HZ and PHN in Sweden during 2011, respectively. The corresponding number for patients 50 years and older with a diagnosis of HZ was 20,446. The incidence of HZ is clearly higher for the group of patients older than 50 years compared to the whole population with 577 and 315 cases per 100,000 persons, respectively (Fig. 1). The incidence of PHN was only estimated for patients older than 50 years to 81 cases per 100,000 persons.Fig. 1

Bottom Line: Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages.The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient.The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

View Article: PubMed Central - PubMed

Affiliation: Mapi Group, Stockholm, Klarabergsviadukten 90D, SE-111 64, Stockholm, Sweden. Jonas.nilsson@optum.com.

ABSTRACT

Background: The societal economic burden of herpes zoster in Sweden is not well described today. This study is a top-down analysis of Swedish registers with the objective to describe the burden of herpes zoster and post-herpetic neuralgia in Sweden during 2011.

Methods: Data for inpatient care; outpatient primary and specialized cares; the prescriptions of drugs, sick leave and the number or diagnostic tests were collected from Swedish national databases. The incidence of the disease was estimated based on the number of prescriptions of antiviral drugs.

Results: The incidence of herpes zoster was estimated to 315 and 577 cases per 100,000 people for patients at all ages and > = 50 years, respectively. Almost 30,000 patients at all ages were diagnosed with herpes zoster and the societal cost to treat these patients, including the cost to treat those patients who later developed post-herpetic neuralgia, added up to nearly 227 MSEK (31.6 M€) which corresponds to 7,600 SEK (€870) per patient. The main contributors to the total cost for the treatment of HZ patients were primary care (43 %); sick leave (28 %); hospitalization (10 %) and specialist care (7 %). Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages. The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient.

Conclusions: The current study demonstrates that the burden of herpes zoster is significant in Sweden. The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

Show MeSH
Related in: MedlinePlus